Compass Therapeutics Q1 net loss $7.8M; cash $175M funds operations into 2026

Compass Therapeutics, Inc.

Net loss of $7.8M ($0.06 per share) vs $7.2M in Q1 2022; R&D spend up 50% to $6.6M on CTX-009.
Cash and marketable securities $175M at March 31, 2023, providing runway into 2026.
Phase 2/3 of CTX-009 in biliary tract cancers enrolling; top-line data expected H1 2024.
Phase 2 CTX-009 in colorectal cancer initial data expected Q3 2023; ASCO GI data showed 37.5% ORR.
Appointed Minori Rosales as SVP Head of Clinical Development and Richard Lindahl to board as Audit Chair.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Compass Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $7.8 million, EPS $0.06 per share.

Period: the first quarter ended March 31, 2023
Net income: $7.8 million
EPS: $0.06 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2023, was $7.8 million or $0.06 per share, compared to $7.2 million or $0.07 per share for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-002866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.